ENSC
Ensysce Biosciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website ensysce.com
- Employees(FY) 7
- ISIN US2936024056
Performance
-2.8%
1W
+268.79%
1M
+63.93%
3M
+5.08%
6M
-38.14%
YTD
-27.14%
1Y
Profile
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.
Technical Analysis of ENSC 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-12 03:15
- 2024-11-06 19:00
- 2024-10-07 20:00
- 2024-10-01 20:00
- 2024-09-27 04:30
Ensysce Biosciences Receives Notice from Nasdaq(Accesswire)
- 2024-09-23 20:00
- 2024-09-18 19:00
- 2024-09-12 20:00
- 2024-08-28 20:00
- 2024-08-28 20:00
- 2024-08-27 02:30
- 2024-08-26 20:00
- 2024-08-22 20:00
- 2024-08-14 04:15
- 2024-08-07 20:25
- 2024-07-22 20:00
- 2024-07-08 20:00
- 2024-06-26 20:00
- 2024-06-24 20:00
- 2024-06-23 22:52
- 2024-06-05 20:00
- 2024-06-02 20:00
- 2024-05-27 20:00
- 2024-05-19 20:00
- 2024-05-12 20:00
- 2024-04-24 20:00
- 2024-04-18 20:00
- 2024-04-08 20:00
- 2024-03-17 22:53
- 2024-03-14 20:00
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.